NCT04625907Toboroz1/2. fázis
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2024. máj. 23. · Több mint 12 hónapja nem frissült - kérdezd meg a helyszínt, nyitott-e még
Rövid összefoglaló (regiszter, angolul)
FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)
- Állapot (regiszter)
- Toboroz
- Fázis (regiszter)
- 1/2. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 1672 (tervezett)
- Első benyújtás
- 2019. nov. 22.
- Kezdés
- 2020. szept. 17.
- Elsődleges befejezés
- 2030. jún.
- Fő szponzor
- University of Birmingham
- Betegségek
- Gyermekkori daganatok, Szarkóma
- NCT-szám
- NCT04625907
- EU CT-szám
- 2024-510579-40-00
- EudraCT-szám
- 2018-000515-24
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 1/2. fázis
- Tervezett résztvevők: 1672
- 2020. szept. 17. és az elsődleges befejezés (2030. jún.) között
- 226 helyszín, 22 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Kiket keres a vizsgálat
- Histologically confirmed diagnosis of RMS (except pleomorphic RMS)
- Written informed consent from the patient and/or the parent/legal guardian
- Phase 1b Dose Finding - IRIVA Inclusion
- Entered in to the FaR-RMS study at diagnosis
- Very High Risk disease
- Age >12 months and ≤25 years
- No prior treatment for RMS other than surgery
- Medically fit to receive treatment
- Adequate hepatic function:
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age, unless the patient is known to have Gilbert's syndrome
- ALT or AST < 2.5 X ULN for age
- Absolute neutrophil count ≥1.0x 109/L
- Platelets ≥ 80 x 109/L
- Adequate renal function: estimated or measured creatinine clearance ≥60 ml/min/1.73 m2
- Documented negative pregnancy test for female patients of childbearing potential
- Patient agrees to use contraception during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where patient is sexually active
- Written informed consent from the patient and/or the parent/legal guardian
- Exclusion
- Weight <10kg
- Active > grade 2 diarrhoea
- Prior allo- or autologous Stem Cell Transplant
- Uncontrolled inter-current illness or active infection
- Pre-existing medical condition precluding treatment
- Urinary outflow obstruction that cannot be relieved prior to starting treatment
- Active inflammation of the urinary bladder (cystitis)
- Known hypersensitivity to any of the treatments or excipients
- Second malignancy
- Pregnant or breastfeeding women
- Frontline chemotherapy randomisation Very High Risk - CT1a Inclusion
- Entered in to the FaR-RMS study at diagnosis
- Very High Risk disease
- Age ≥ 6 months
- Available for randomisation ≤60 days after diagnostic biopsy/surgery
- No prior treatment for RMS other than surgery
- Medically fit to receive treatment
- Adequate hepatic function :
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age, unless the patient is known to have Gilbert's syndrome
- Absolute neutrophil count ≥1.0x 109/L (except in patients with documented bone marrow disease)
- Platelets ≥ 80 x 109/L (except in patients with documented bone marrow disease)
- Fractional Shortening ≥ 28%
- Documented negative pregnancy test for female patients of childbearing potential
- Patient agrees to use contraception during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where patient is sexually active
- Written informed consent from the patient and/or the parent/legal guardian
- Exclusion
- Active > grade 2 diarrhoea
- Prior allo- or autologous Stem Cell Transplant
- Uncontrolled inter-current illness or active infection
- Pre-existing medical condition precluding treatment
- Urinary outflow obstruction that cannot be relieved prior to starting treatment
- Active inflammation of the urinary bladder (cystitis)
- Known hypersensitivity to any of the treatments or excipients
- Second malignancy
- Pregnant or breastfeeding women
- Frontline chemotherapy randomisation High Risk - CT1b Inclusion
- Entered in to the FaR-RMS study at diagnosis
- High Risk disease
- Age ≥ 6 months
- Available for randomisation ≤60 days after diagnostic biopsy/surgery
- No prior treatment for RMS other than surgery
- Medically fit to receive treatment
- Adequate hepatic function :
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age, except if the patient is known to have Gilbert's syndrome
- Absolute neutrophil count ≥1.0x 109/L
- Platelets ≥ 80 x 109/L
- Documented negative pregnancy test for female patients of childbearing potential
- Patient agrees to use contraception during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where patient is sexually active
- Written informed consent from the patient and/or the parent/legal guardian
- Exclusion
- Active > grade 2 diarrhoea
- Prior allo- or autologous Stem Cell Transplant
- Uncontrolled inter-current illness or active infection
- Pre-existing medical condition precluding treatment
- Urinary outflow obstruction that cannot be relieved prior to starting treatment
- Active inflammation of the urinary bladder (cystitis)
- Known hypersensitivity to any of the treatments or excipients
- Second malignancy
- Pregnant or breastfeeding women
- Frontline Radiotherapy Note: eligible patients may enter multiple radiotherapy randomisations.
- Radiotherapy Inclusion - for all radiotherapy randomisations
- Entered in to the FaR-RMS study (at diagnosis or prior to radiotherapy randomisation)
- Very High Risk, High Risk and Standard Risk disease
- ≥ 2 years of age
- Receiving frontline induction treatment as part of the FaR-RMS trial or with a IVA/IVADo based chemotherapy regimen patients for whom. Note that patients for whom ifosfamide has been replaced with cyclophosphamide will be eligible
- Patient assessed as medically fit to receive the radiotherapy
- Documented negative pregnancy test for female patients of childbearing potential
- Patient agrees to use contraception during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where patient is sexually active
- Written informed consent from the patient and/or the parent/legal guardian
- Radiotherapy Exclusion - for all radiotherapy randomisations
- Prior allo- or autologous Stem Cell Transplant
- Second malignancy
- Pregnant or breastfeeding women
- Receiving radiotherapy as brachytherapy
- RT1a Specific Inclusion
- Primary tumour deemed resectable (predicted R0/ R1 resection feasible) after 3 cycles of induction chemotherapy (6 cycles for metastatic disease)
- Adjuvant radiotherapy required in addition to surgical resection (local decision).
- Available for randomisation after cycle 3 and prior to the start of cycle 6 of induction chemotherapy for localised disease, or after cycle 6 and prior to the start of cycle 9 for metastatic disease
- RT1b Specific Inclusion
- Primary tumour deemed resectable (predicted R0/R1 resection) after 3 cycles of induction chemotherapy (6 cycles for metastatic disease).
- Adjuvant radiotherapy required in addition to surgical resection (local decision)
- Higher Local Failure Risk (HLFR) based on presence of either of the following criteria:
- Unfavourable site
- Age ≥ 18yrs
- Available for randomisation after cycle 3 and prior to the start of cycle 6 of induction chemotherapy for localised disease, or after cycle 6 and prior to the start of cycle 9 for metastatic disease
- RT1c Specific Inclusion
- Primary radiotherapy indicated (local decision)
- Higher Local Failure Risk (HLFR) based on either of the following criteria:
- Unfavourable site
- Age ≥ 18yrs
- Available for randomisation after cycle 3 and prior to the start of cycle 6 of induction chemotherapy for localised disease, or after cycle 6 and prior to the start of cycle 9 for metastatic disease
- RT2
- Available for randomisation after cycle 6 and before the start of cycle 9 of induction chemotherapy.
- Unfavourable metastatic disease, defined as Modified Oberlin Prognostic Score 2-4
- Note: Definition of metastatic lesions for RT2 eligibility
- Modified Oberlin Prognostic Score (1 point for each adverse factor):
- Age ≥10y
- Extremity, Other, Unidentified Primary Site
- Bone and/ or Bone Marrow involvement
- ≥3 metastatic sites
- Unfavourable metastatic disease: 2- 4 adverse factors Favourable metastatic disease: 0-1 adverse factors
- Maintenance chemotherapy (Very High Risk) - CT2a Inclusion Randomisation must take place during the 12th cycle of maintenance chemotherapy.
- Entered in to the FaR-RMS study (at diagnosis or at any subsequent time point)
- Very High Risk disease
- Received frontline induction chemotherapy as part of the FaR-RMS trial or with a IVA/IVADo based chemotherapy regimen
- Patients for whom ifosfamide has been replaced with cyclophosphamide will be eligible
- Completed 11 cycles of VnC maintenance treatment (either oral or IV regimens)
- No evidence of progressive disease
- Absence of severe vincristine neuropathy - i.e requiring discontinuation of vincristine treatment)
- Medically fit to continue to receive treatment
- Patient agrees to use contraception during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where patient is sexually active
- Written informed consent from the patient and/or the parent/legal guardian
- Exclusion
- Prior allo- or autologous Stem Cell Transplant
- Uncontrolled intercurrent illness or active infection
- Urinary outflow obstruction that cannot be relieved prior to starting treatment
- Active inflammation of the urinary bladder (cystitis)
- Second malignancy
- Pregnant or breastfeeding women
- Maintenance chemotherapy (High Risk) - CT2b Randomisation must take place during the 6th cycle of maintenance chemotherapy. Inclusion
- Entered in to the FaR-RMS study (at diagnosis or at any subsequent time point)
- High Risk disease
- Received frontline induction chemotherapy as part of the FaR-RMS trial or with a IVA based chemotherapy regimen. Note that patients for whom ifosfamide has been replaced with cyclophosphamide will be eligible
- Completed 5 cycles of VnC maintenance treatment
- No evidence of progressive disease
- Absence of severe vincristine neuropathy i.e. requiring discontinuation of vincristine treatment
- Medically fit to continue to receive treatment
- Patient agrees to use contraception during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where patient is sexually active
- Written informed consent from the patient and/or the parent/legal guardian
- Exclusion
- Prior allo- or autologous Stem Cell Transplant
- Uncontrolled inter current illness or active infection
- Urinary outflow obstruction that cannot be relieved prior to starting treatment
- Active inflammation of the urinary bladder (cystitis)
- Second malignancy
- Pregnant or breastfeeding women
- CT3 Relapsed Chemotherapy
- Inclusion:
- Entered in to the FaR-RMS study (at diagnosis or at any subsequent time point)
- First or subsequent relapse of histologically verified RMS
- Age ≥ 6 months
- Measurable or evaluable disease
- No cytotoxic chemotherapy or other investigational medicinal product (IMP) within previous three weeks: within two weeks for vinorelbine and cyclophosphamide maintenance chemotherapy
- Medically fit to receive trial treatment
- Documented negative pregnancy test for female patients of childbearing potential within 7 days of planned randomisation
- Patient agrees to use contraception during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where patient is sexually active
- Written informed consent from the patient and/or the parent/legal guardian
- Exclusion:
- Progression during frontline therapy without previous response (=Refractory to first line treatment)
- Prior regorafenib or temozolomide
- Active > grade 1 diarrhoea
- ALT or AST >3.0 x upper limit normal (ULN)
- Bilirubin, Total >1.5 x ULN; total bilirubin is allowed up to 3 x ULN if Gilbert's syndrome is documented
- Patients with unstable angina or new onset angina (within 3 months of planned date of randomisation), recent myocardial infarction (within 6 months of randomisation) and those with cardiac failure New York Heart Association (NYHA) Classification 2 or higher Cardiac abnormalities such as congestive heart failure (Modified Ross Heart Failure Classification for Children = class 2) and cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted)
- Uncontrolled hypertension > 95th centile for age and gender
- Prior allo- or autologous Stem Cell Transplant
- Uncontrolled inter-current illness or active infection
- Pre-existing medical condition precluding treatment
- Known hypersensitivity to any of the treatments or excipients
- Second malignancy
- Pregnant or breastfeeding women
Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (226)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Medical University of Graz | Graz | Ausztria | Toboroz |
| Medizinische Universitaet Innsbruck | Innsbruck | Ausztria | Toboroz |
| Johannes Kepler University Linz | Linz | Ausztria | Toboroz |
| Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH | Salzburg | Ausztria | Toboroz |
| St. Anna Kinderspital GmbH | Vienna | Ausztria | Toboroz |
| Queensland Children's Hospital | Brisbane | Ausztrália | Toboroz |
| Chris O'Brien Lifehouse | Camperdown | Ausztrália | Toboroz |
| Monash Children's Hospital | Clayton | Ausztrália | Toboroz |
| Peter MacCallum Cancer Centre | Melbourne | Ausztrália | Toboroz |
| Royal Childrens Hospital Melbourne | Melbourne | Ausztrália | Toboroz |
| John Hunter Children's Hospital | New Lambton Heights | Ausztrália | Toboroz |
| Perth Children's Hospital | Perth | Ausztrália | Toboroz |
| The Childrens Hospital At Westmead | Sydney | Ausztrália | Toboroz |
| Sydney Children's Hospital | Sydney | Ausztrália | Toboroz |
| Westmead Hospital | Westmead | Ausztrália | Toboroz |
| Princess Alexandra Hospital | Woolloongabba | Ausztrália | Toboroz |
| Association Hospitaliere De Bruxelles Hopital Universitaire Des Enfants Reine Fabiola | Brussels | Belgium | Toboroz |
| Antwerp University Hospital | Edegem | Belgium | Toboroz |
| Universitair Ziekenhuis Gent | Gent | Belgium | Toboroz |
| UZ Leuven | Leuven | Belgium | Toboroz |
| Centre Hospitalier Regional de la Citadelle | Liège | Belgium | Toboroz |
| CHC MontLégia | Liège | Belgium | Toboroz |
| Cliniques Universitaires Saint-Luc | Sint-Lambrechts-Woluwe | Belgium | Toboroz |
| Kantonsspital Aarau | Aarau | Svájc | Toboroz |
| Universitats-kinderspital Bieder Basel (UKBB) | Basel | Svájc | Toboroz |
| Ospedale San Giovanni | Bellinzona | Svájc | Toboroz |
| Inselspital Bern | Bern | Svájc | Toboroz |
| HUG-Hôpitaux Universitaires de Genève | Geneva | Svájc | Toboroz |
| Centre Hospitalier Universitaire Vaudois Chuv Lausanne | Lausanne | Svájc | Toboroz |
| Luzerner Kantonspital - Kinderspital Luzern | Lucerne | Svájc | Toboroz |
| Ostschweizer Kinderspital | Sankt Gallen | Svájc | Toboroz |
| Universitaetsspital Zürich | Zurich | Svájc | Toboroz |
| Fakultni nemocnice Brno | Brno | Csehország | Toboroz |
| Fakultni nemocnice v Motole | Prague | Csehország | Toboroz |
| Universitaetsklinikum Aachen AöR | Aachen | Németország | Toboroz |
| Universitaetsklinikum Augsburg | Augsburg | Németország | Toboroz |
| HELIOS Klinikum Berlin Buch GmbH | Berlin | Németország | Toboroz |
| Charite Universitaetsmedizin Berlin KöR | Berlin | Németország | Toboroz |
| Universitaetsklinikum Bonn AöR | Bonn | Németország | Toboroz |
| Gesundheit Nord gGmbH Klinikverbund Bremen | Bremen | Németország | Toboroz |
| Klinikum Chemnitz gGmbH | Chemnitz | Németország | Toboroz |
| Kliniken der Stadt Koeln gGmbH | Cologne | Németország | Toboroz |
| Klinikum Dortmund gGmbH | Dortmund | Németország | Toboroz |
| Technische Universitaet Dresden | Dresden | Németország | Toboroz |
| Universitaetsklinikum Erlangen AöR | Erlangen | Németország | Toboroz |
| Universitätsklinikum Essen | Essen | Németország | Toboroz |
| Goethe University Frankfurt | Frankfurt Am Main | Németország | Toboroz |
| Medical Center- University of Freiburg | Freiburg im Breisgau | Németország | Toboroz |
| Universitaetsklinikum Giessen und Marburg GmbH | Giessen | Németország | Toboroz |
| Universitaetsmedizin Goettingen | Goettingen | Németország | Toboroz |
| Universitätsmedizin Greifswald | Greifswald | Németország | Toboroz |
| Martin-Luther-Universitaet Halle-Wittenberg | Halle (Saale) | Németország | Toboroz |
| University Medical Center Hamburg-Eppendorf | Hamburg | Németország | Toboroz |
| Universitätsklinikum Hamburg-Eppendorf | Hamburg | Németország | Toboroz |
| Medizinische Hochschule Hannover | Hanover | Németország | Toboroz |
| Universitätsklinikum Heidelberg | Heidelberg | Németország | Toboroz |
| Universitätsklinikum Heidelberg Zentrum für Kinder- und Jugendmedizin Kinderheilkunde III | Heidelberg | Németország | Toboroz |
| Universitaet Des Saarlandes | Homburg | Németország | Toboroz |
| Universitaetsklinikum Jena KöR | Jena | Németország | Toboroz |
| Klinikum Kassel GmbH | Kassel | Németország | Toboroz |
| Universitaetsklinikum Schleswig-Holstein AöR | Kiel | Németország | Toboroz |
| Uniklinik Köln | Köln | Németország | Toboroz |
| Universitaet Leipzig | Leipzig | Németország | Toboroz |
| Universitaetsklinikum Schleswig-Holstein AöR | Luebeck | Németország | Toboroz |
| Otto Von Guericke Universitaet Magdeburg | Magdeburg | Németország | Toboroz |
| Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR | Mainz | Németország | Toboroz |
| Universitaetsklinikum Mannheim GmbH | Mannheim | Németország | Toboroz |
| Universitaet Muenster | Muenster | Németország | Toboroz |
| München Klinik gGmbH Schwabing Klinikum rechts der Isar der Technischen Universität Muenchen | München | Németország | Toboroz |
| Klinikum der Universitaet Muenchen AöR | Munich | Németország | Toboroz |
| Universitaetsklinikum Regensburg AöR | Regensburg | Németország | Toboroz |
| Universitätsmedizin Rostock | Rostock | Németország | Toboroz |
| Rostock University Medical Center | Rostock | Németország | Toboroz |
| Klinikum Stuttgart | Stuttgart | Németország | Toboroz |
| Klinikum Der Landeshauptstadt Stuttgart gKAöR | Stuttgart | Németország | Toboroz |
| Universitätsklinikum Tübingen | Tübingen | Németország | Toboroz |
| Universitaetsklinikum Tuebingen AöR | Tuebingen | Németország | Toboroz |
| Universitaetsklinikum Ulm AoR | Ulm | Németország | Toboroz |
| Universitaetsklinikum Wuerzburg AöR | Wuerzburg | Németország | Toboroz |
| Region Midtjylland | Aarhus N | Dánia | Toboroz |
| Rigshospitalet | Copenhagen Oe | Dánia | Toboroz |
| Region Hovedstadens Apotek Herlev Hospital | Herlev | Dánia | Toboroz |
| Hospital Universitario de Cruces | Barakaldo | Spanyolország | Toboroz |
| Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca | Barcelona | Spanyolország | Toboroz |
| Hospital Sant Joan De Deu Barcelona | Esplugues de Llobregat | Spanyolország | Toboroz |
| Hospital General Universitario Gregorio Marañón | Madrid | Spanyolország | Toboroz |
| Hospital Universitario La Paz | Madrid | Spanyolország | Toboroz |
| Hospital Infantil Universitario Nino Jesus | Madrid | Spanyolország | Toboroz |
| Hospital Universitario Regional de Málaga | Málaga | Spanyolország | Toboroz |
| University Hospital Virgen Del Rocio S.L. | Sevilla | Spanyolország | Toboroz |
| Hospital Universitario Y Politecnico La Fe | Valencia | Spanyolország | Toboroz |
| Hospital Universitario Miguel Servet | Zaragoza | Spanyolország | Toboroz |
| HUS-Yhtymae | Helsinki | Finnország | Toborzás még nem indult |
| Pohjois-Savon hyvinvointialue | Kuopio | Finnország | Toborzás még nem indult |
| Pohjois-Pohjanmaan hyvinvointialue | Oulu | Finnország | Toborzás még nem indult |
| Pirkanmaan hyvinvointialue | Tampere | Finnország | Toborzás még nem indult |
| Varsinais-Suomen hyvinvointialue | Turku | Finnország | Toborzás még nem indult |
| Centre Hospitalier Universitaire Amiens Picardie | Amiens Cedex 1 | Franciaország | Toboroz |
| Centre Hospitalier Universitaire D Angers | Angers Cedex 9 | Franciaország | Toboroz |
| CHU Besancon | Besancon Cedex | Franciaország | Toboroz |
| CHU de Bordeaux - Hôpital Pellegrin | Bordeaux | Franciaország | Toboroz |
| Institut Bergonie | Bordeaux | Franciaország | Toboroz |
| Centre Hospitalier Régional et Universitaire de Brest | Brest | Franciaország | Toboroz |
| Centre Francois Baclesse | Caen Cedex 5 | Franciaország | Toboroz |
| Centre Hospitalier Universitaire De Caen Normandie | Caen Cedex 9 | Franciaország | Toboroz |
| CHU d'Estaing | Clermont-Ferrand | Franciaország | Toboroz |
| Centr Georges Francois Leclerc | Dijon | Franciaország | Toboroz |
| Centre Hospitalier Universitaire de Dijon | Dijon | Franciaország | Toboroz |
| Centre Oscar Lambret | Lille | Franciaország | Toboroz |
| Centre Leon Berard | Lyon | Franciaország | Toboroz |
| Hôpital La Timone - APHM | Marseille | Franciaország | Toboroz |
| Institut Regional Du Cancer de Montpellier | Montpellier | Franciaország | Toboroz |
| CHU de Montpellier | Montpellier Cedex 05 | Franciaország | Toboroz |
| Centre Hospitalier Universitaire de Nantes | Nantes | Franciaország | Toboroz |
| Centre Hospitalier Universitaire de Nice | Nice | Franciaország | Toboroz |
| Centre Antoine Lacassagne | Nice Cedex 2 | Franciaország | Toboroz |
| Institut Curie | Paris | Franciaország | Toboroz |
| Hopital Cochin Saint Vincent De Paul | Paris | Franciaország | Toboroz |
| Trousseau Hospital | Paris | Franciaország | Toboroz |
| Centre Hospitalier Universitaire de Bordeaux | Pessac | Franciaország | Toboroz |
| CHU de Poitiers | Poitiers Cedex | Franciaország | Toboroz |
| Centre Hospitalier Universitaire Reims | Reims | Franciaország | Toboroz |
| Centre Eugène Marquis | Rennes | Franciaország | Toboroz |
| Centre Hospitalier Universitaire de Rennes | Rennes | Franciaország | Toboroz |
| Centre Hospitalier Universitaire Rouen | Rouen Cedex | Franciaország | Toboroz |
| Centre Hospitalier Universitaire De La Reunion | Saint-Denis | Franciaország | Toboroz |
| CHU Saint Etienne Hôpital Nord | Saint-Etienne | Franciaország | Toboroz |
| Institut De Cancerologie De L Ouest | Saint-Herblain Cedex | Franciaország | Toboroz |
| Institut de Cancérologie Strasbourg Europe | Strasbourg | Franciaország | Toboroz |
| Hôpital de Hautepierre - Strasbourg | Strasbourg | Franciaország | Toboroz |
| Oncopole Claudius Regaud | Toulouse | Franciaország | Toboroz |
| Centre Hospitalier Universitaire De Toulouse | Toulouse Cedex 9 | Franciaország | Toboroz |
| CHRU Tours | Tours | Franciaország | Toboroz |
| CHRU De Nancy | Vandoeuvre Les Nancy | Franciaország | Toboroz |
| Institut De Cancerologie De Lorraine | Vandouvre Les Nancy | Franciaország | Toboroz |
| Institut Gustave Roussy | Villejuif Cedex | Franciaország | Toboroz |
| Royal Aberdeen Children's Hospital | Aberdeen | Egyesült Királyság | Toboroz |
| Royal Belfast Hospital for Sick Children | Belfast | Egyesült Királyság | Toborzás még nem indult |
| Belfast City Hospital | Belfast | Egyesült Királyság | Toborzás még nem indult |
| Birmingham Children's Hospital | Birmingham | Egyesült Királyság | Toboroz |
| The Queen Elizabeth Hospital | Birmingham | Egyesült Királyság | Toborzás még nem indult |
| Bristol Royal Hospital for Children | Bristol | Egyesült Királyság | Toboroz |
| Bristol Haematology and Oncology Centre | Bristol | Egyesült Királyság | Toboroz |
| Addenbrooke's Hospital | Cambridge | Egyesült Királyság | Toboroz |
| Velindre Hospital | Cardiff | Egyesült Királyság | Toboroz |
| Noah's Ark Children's Hospital for Wales | Cardiff | Egyesült Királyság | Toboroz |
| Royal Hospital for Children and Young People | Edinburgh | Egyesült Királyság | Toboroz |
| Royal Hospital for Children Glasgow | Glasgow | Egyesült Királyság | Toboroz |
| Beatson West of Scotland Cancer Centre | Glasgow | Egyesült Királyság | Toboroz |
| Leeds General Infirmary | Leeds | Egyesült Királyság | Toboroz |
| St James's University Hospital | Leeds | Egyesült Királyság | Toboroz |
| Leicester Royal Infirmary | Leicester | Egyesült Királyság | Toboroz |
| Alder Hey Children's Hospital | Liverpool | Egyesült Királyság | Toboroz |
| University College London Hospital | London | Egyesült Királyság | Toboroz |
| Royal Marsden Hospital - London | London | Egyesült Királyság | Toboroz |
| Great Ormond Street Hospital for Children | London | Egyesült Királyság | Toboroz |
| Royal Manchester Children's Hospital | Manchester | Egyesült Királyság | Toboroz |
| Christie Hospital | Manchester | Egyesült Királyság | Toboroz |
| Clatterbridge Cancer Centre | Metropolitan Borough of Wirral | Egyesült Királyság | Toboroz |
| Royal Victoria Infirmary | Newcastle upon Tyne | Egyesült Királyság | Toboroz |
| Queen's Medical Centre, Nottingham | Nottingham | Egyesült Királyság | Toboroz |
| Nottingham City Hospital | Nottingham | Egyesült Királyság | Toboroz |
| John Radcliffe Hospital | Oxford | Egyesült Királyság | Toboroz |
| Sheffield Children's Hospital | Sheffield | Egyesült Királyság | Toboroz |
| Weston Park Hospital | Sheffield | Egyesült Királyság | Toborzás még nem indult |
| Southampton General Hospital | Southampton | Egyesült Királyság | Toboroz |
| Royal Marsden Hospital | Sutton | Egyesült Királyság | Toboroz |
| Athens General Children's Hospital Panagioti And Aglaia Kyriakou | Athens | Görögország | Toboroz |
| Nosokomeio Paidon I Agia Sofia | Athens | Görögország | Toboroz |
| University General Hospital of Heraklion | Heraklion | Görögország | Toboroz |
| Mitera S.A. | Marousi | Görögország | Toboroz |
| Ippokratio General Hospital of Thessaloniki | Thessaloniki | Görögország | Toboroz |
| University General Hospital of Thessaloniki - AHEPA | Thessaloniki | Görögország | Toboroz |
| Children's Health Ireland | Dublin 12 | Írország | Toboroz |
| Rambam Health Care Campus | Haifa | Izrael | Toboroz |
| Hadassah University Medical Centre | Jerusalem | Izrael | Toboroz |
| Schneider Medical Centre | Petah Tikva | Izrael | Toboroz |
| Dana Children's Hospital, Tel Aviv Sourasky Medical Center | Tel Aviv | Izrael | Toboroz |
| Chaim Sheba Medical Centre | Tel HaShomer | Izrael | Toboroz |
| Azienda Ospedaliero-Universitaria delle Marche | Ancona | Olaszország | Toboroz |
| Azienda Ospedaliero Universitaria Consorziale Policlinico Di Bari | Bari | Olaszország | Toboroz |
| Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII | Bergamo | Olaszország | Toboroz |
| Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico | Bologna | Olaszország | Toboroz |
| ARNAS G. Brotzu | Cagliari | Olaszország | Toboroz |
| Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania | Catania | Olaszország | Toboroz |
| Azienda Ospedaliera-Universitaria Di Cosenza | Cosenza | Olaszország | Toboroz |
| Azienda Ospedaliera Universitaria Meyer IRCCS | Florence | Olaszország | Toboroz |
| IRCCS Istituto Giannina Gaslini | Genoa | Olaszország | Toboroz |
| Fondazione IRCCS - Istituto Nazionale dei Tumori | Milan | Olaszország | Toboroz |
| Azienda Ospedaliero - Universitaria di Modena | Modena | Olaszország | Toboroz |
| Azienda Ospedaliera Universitaria - Universita degli Studi della Campania Luigi Vanvitelli | Naples | Olaszország | Toboroz |
| Azienda Ospedaliera Santobono Pausilipon | Naples | Olaszország | Toboroz |
| Azienda Ospedaliera di Padova | Padova | Olaszország | Toboroz |
| ARNAS Civico Di Cristina Benfratelli | Palermo | Olaszország | Toboroz |
| Azienda Ospedaliero Universitaria Parma | Parma | Olaszország | Toboroz |
| Fondazione IRCCS Policlinico San Matteo | Pavia | Olaszország | Toboroz |
| Hospital Santa Maria Della Misericordia | Perugia | Olaszország | Toboroz |
| Azienda Ospedaliero Universitaria Pisana | Pisa | Olaszország | Toboroz |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Rome | Olaszország | Toboroz |
| Ospedale Pediatrico Bambino Gesù | Rome | Olaszország | Toboroz |
| Casa Sollievo della Sofferenza | San Giovanni Rotondo | Olaszország | Toboroz |
| Ospedale SS. Annunziata | Taranto | Olaszország | Toboroz |
| Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo | Trieste | Olaszország | Toboroz |
| Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino | Turin | Olaszország | Toboroz |
| Azienda Ospedaliera Universitaria Integrata Verona | Verona | Olaszország | Toboroz |
| Universitair Medisch Centrum Groningen | Groningen | Hollandia | Toboroz |
| Prinses Maxima Centrum voor Kinderoncologie B.V. | Utrecht | Hollandia | Toboroz |
| Haukeland Universitetssykehus | Bergen | Norvégia | Toboroz |
| Oslo University Hospital HF | Oslo | Norvégia | Toboroz |
| University Hospital of North Norway | Tromsø | Norvégia | Toboroz |
| St. Olavs hospital HF | Trondheim | Norvégia | Toboroz |
| Starship Children's Health | Auckland | Új-Zéland | Toboroz |
| Christchurch Hospital | Christchurch | Új-Zéland | Toboroz |
| Centro Hospitalar Universitario de Coimbra | Coimbra | Portugália | Toboroz |
| Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E. | Lisbon | Portugália | Toboroz |
| Centro Hospitalar Universitário de São João | Porto | Portugália | Toboroz |
| Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E. | Porto | Portugália | Toboroz |
| Sahlgrenska University Hospital-Vaestra Goetalandsregionen | Goteborg | Svédország | Toboroz |
| Queen Silvia Childrens Hospital - Sahlgrenska University Hospital - Vaestra Goetalandsregionen | Gothenburg | Svédország | Toboroz |
| Region Skane Skanes Universitetssjukhus | Lund | Svédország | Toboroz |
| Karolinska University Hospital | Solna | Svédország | Toboroz |
| Region Vaesterbotten | Umea | Svédország | Toboroz |
| Uppsala University Hospital | Uppsala | Svédország | Toboroz |
| Linkoping University Hospital | - | Svédország | Toboroz |
| University Medical Center Ljubljana | Ljubljana | Szlovénia | Toboroz |
| Bratislava, National Institute for Children's Diseases | Bratislava | Szlovákia | Toborzás még nem indult |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.